Description
Perflutren is an investigational drug being studied primarily as a contrast agent for ultrasound imaging. In the context of colorectal cancer, it has been investigated in clinical trials focused on liver metastases. The main goal of these studies is to see if specific characteristics observed using ultrasound imaging after perflutren administration can help predict how well the liver tumors will respond to chemotherapy. This involves imaging before treatment and at specific time points (like 2 weeks and 2 months) after starting chemotherapy. The aim is to find non-invasive ways to assess treatment response early on.
Mechanism of Action
Perflutren is a microbubble contrast agent used in ultrasound imaging. It works by enhancing the way ultrasound waves reflect off blood vessels, particularly in tumors. This allows for better visualization of blood flow (perfusion) within the tumor and surrounding tissue. In the context of the clinical trial, it's used to observe perfusion characteristics in liver metastases, which researchers hope can correlate with the tumor's response to chemotherapy. The specific molecular target is not relevant as it is an imaging agent.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.